4DMedical Lands First U.S. Commercial Deployment of CT:VQ

Highlights:

• 4DMedical Ltd. (ASX: 4DX) secured its first U.S. commercial deployment of its FDA-approved CT:VQ lung imaging technology at Stanford University, marking a major milestone in its U.S. rollout.
   
• The company’s shares rose 2.8 per cent to A$1.85 at the time of writing, reflecting investor optimism following the announcement.
   
• The Stanford partnership enables up to 20,000 annual CT scan analyses, positioning 4DMedical to accelerate adoption, reimbursement, and market expansion in the U.S. lung imaging sector.

4DMedical Ltd. (ASX: 4DX) has taken a key step in its U.S. rollout strategy by securing its first commercial deployment of its flagship imaging technology, CT:VQ, at Stanford University. At the time of writing, the share price rose by 2.8 per cent to A$1.85 in response to the announcement.

A Milestone for Lung Imaging

CT:VQ is the company’s first non-contrast computed-tomography-based ventilation-perfusion (V/Q) imaging solution, designed to offer an alternative to traditional nuclear medicine scans. At the time of writing, the deployment at Stanford marks the first commercial contract in the U.S., placing the institution as the anchor site in a planned network of opinion-leader centres.

What It Means for 4DMedical

The Stanford agreement signals the transition from regulatory approval to commercial traction. As part of the agreement, Stanford’s 3D Quantitative Imaging Laboratory (3DQ Lab) is expected to perform as many as 20,000 CT-based analyses each year through the use of 4DMedical’s imaging platform.

This provides validation and momentum for 4DMedical’s aim to integrate CT:VQ into routine radiology workflows and hospitals that lack nuclear-medicine infrastructure. Adoption at Stanford could accelerate evidence-generation, reimbursement positioning and early uptake. At the time of writing, the broader market opportunity in the U.S. for ventilation-perfusion imaging is estimated at over US$1 billion annually.

Strategic Outlook & Investor Perspective

For investors and stakeholders, this development strengthens 4DMedical’s commercial narrative: from novel imaging software to real-world deployment. The scientific validation is backed by FDA clearance and early institutional adoption, which helps reduce execution risk. Key focus areas going forward will include scaling deployment beyond Stanford, expanding reimbursement pathways, securing additional hospital contracts, and demonstrating clinical and cost-benefits relative to legacy nuclear-medicine V/Q scans.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com